PIGF and Flt-1 as prognostic parameters for cardiovascular illnesses

摘要

A method for diagnosis, risk assessment and/or monitoring of vascular diseases of atherosclerotic etiology, and/or evaluating the likelihood of developing such diseases, involves quantifying placental growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) in a sample from the patient (in either order); and determining the ratio of the two values. An independent claim is included for a diagnostic kit containing agent(s) for quantifying PlGF and agent(s) for quantifying sPlt-1 in a sample from a patient with a vascular diseases of atherosclerotic etiology.